CDK4/6 Inhibitors: What Is the Best Cocktail?

Clin Cancer Res. 2019 Jan 1;25(1):6-8. doi: 10.1158/1078-0432.CCR-18-2177. Epub 2018 Aug 16.

Abstract

CDK4/6 inhibitors have shown great potential in the new armamentarium against cancer. However, their effect as single agents is limited, and the hopes are on new combinatory strategies. Recent data suggest that inhibiting mTOR may significantly cooperate with cell-cycle arrest in a variety of cancers.See related article by Song et al., p. 403.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Bile Duct Neoplasms*
  • Bile Ducts, Intrahepatic*
  • Cholangiocarcinoma*
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6
  • Humans
  • Protein Kinase Inhibitors
  • TOR Serine-Threonine Kinases

Substances

  • Protein Kinase Inhibitors
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4
  • Cyclin-Dependent Kinase 6